| Question | Answer |
|---|---|
| ? is not a general metabolic or structural target for antimicrobial drugs | Lipid synthesis inhibition |
| ? is not a common characteristic used in the selection of an antimicrobial drug | penetration of the blood brain barrier |
| The term "bacteriostatic" means that bacteria | no longer can multiply |
| when two antibiotics are given together to increase the therapeutic effect the phenomenon is referred to as | synergism |
| ? is not a mechanism of resistance used by microbes | change in ribosome composition |
| ? is a synthetic antimictobial drug | Quinolone |
| Cephalosporins have ? generations of developed agents | 4 |
| ? is effective against mycobacteria | Rifampin |
| ? is an antiviral agent | Amantadine |
| ? is effective against Candida albicans | Echinocandins |
| Prevent microbes from growing | Bacteriostatic |
| Antimicrobial drugs that kill microorganisms are | Bactericidal |
| ? of a drug is its ability to cross biological barriers | Efficacy |
| Natural products that have been chemically modified in the lab to improve effectiveness | Semisynthetic |
| E. coli | UTI |
| Staphylococcus aureus | TSS |
| Streptococcus pyogenes | Strep throat, rheumatic fever |
| Streptococcus pneumonia | Pneumonia |
| Bacillus | Anthrax |
| Clostridium | Tetanus, gas gangrene |
| Corynebacterium | Diphtheria |
| Mycobacterium | TB |
